

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12P 7/64, A61K 31/20, A23L 1/30</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/03671</b> <b>(43) International Publication Date:</b> 29 January 1998 (29.01.98)
<b>(21) International Application Number:</b> PCT/JP97/01946 <b>(22) International Filing Date:</b> 6 June 1997 (06.06.97) <b>(30) Priority Data:</b> 8/193516 23 July 1996 (23.07.96) JP <b>(71) Applicants (for all designated States except US):</b> NAGASE BIOCHEMICALS, LTD. [JP/JP]; 1-17, Shinmachi 1-chome, Nishi-ku, Osaka-shi, Osaka 550-91 (JP). SUNTORY LIMITED [JP/JP]; 1-40, Dojimahama 2-chome, Kita-ku, Osaka-shi, Osaka 530 (JP). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TANAKA, Satoshiro [JP/JP]; 400, Kumon, Ichinomiya-cho, Shiso-gun, Hyogo 671-41 (JP). YAGUCHI, Toshiaki [JP/JP]; Suntory Ltd. Research Center, 1-1-1, Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka 618 (JP). SHIMIZU, Sakayu [JP/JP]; 6-9, Tokiwayamashita-cho, Ukyo-ku, Kyoto-shi, Kyoto 604 (JP). SOGO, Tsutomu [JP/JP]; 7-2-9, Mikanodai, Nishi-ku, Kobe-shi, Hyogo 651-22 (JP). FUJIKAWA, Shigeaki [JP/JP]; 17-26, Hiyoshidainanaban-cho, Takatsuki-shi, Osaka 569-11 (JP).		<b>(74) Agent:</b> YAMAMOTO, Shusaku; Crystal Tower, 15th floor, 2-27, Shiromi 1-chome, Chuo-ku., Osaka-shi, Osaka 540 (JP). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> With international search report.
<b>(54) Title:</b> PROCESS FOR PREPARING DOCOSAHEXAENOIC ACID AND DOCOSAPENTAENOIC ACID  <b>(57) Abstract</b>  A process for preparing lipids which contain docosahexaenoic acid (DHA) and/or docosapentaenoic acid (DPA) is disclosed. The process includes the steps of cultivating in a medium a microorganism which belongs to the genus <i>Ulkenia</i> having the ability to produce DHA and/or DPA and recovering the lipids from the culture. The process may further include the step of separating DHA and/or DPA from the lipids.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

DESCRIPTIONPROCESS FOR PREPARING DOCOSAHEXAENOIC ACID  
AND DOCOSAPENTAENOIC ACID

5

TECHNICAL FIELD

The present invention relates to a process for preparing lipids containing docosahexaenoic acid (hereinafter, also referred to as "DHA") and/or docosapentaenoic acid (hereinafter, also referred to as "DPA") by cultivating a microorganism, as well as a process for preparing DHA and/or DPA from the lipids. The present invention also relates to a microorganism belonging to the genus Ulkenia having the ability to produce the lipids.

BACKGROUND ART

DHA is contained in oil from fish belonging to the group of blue fish. Particularly, DHA is contained in the oil from sardines or tuna, in which DHA is contained in an amount of around 20%.

Recently, due to the discovery of fish material containing a high concentration of DHA such as the orbital fat of tuna, or due to the progress in technology for producing highly purified fatty acids, intensive efforts have been made to elucidate the physiological functions of DHA, and to investigate its practical use. It has become apparent that the physiological functions of DHA include an effect of lowering cholesterol, an anticoagulant effect and a carcinostatic effect. In relation to the metabolic system of brain, it has also become appar-

- 2 -

ent that DHA is effective in improving memory and learning, preventing senile dementia, and treating Alzheimer's disease. In addition, it has been proved that DHA is an essential fatty acid for the growth of fry. For the  
5 reasons mentioned above, DHA is used in various foods, feedstuffs and baits.

DPA is also known to be contained in fish oil, although the content is extremely low. Most of the  
10 physiological functions of DPA are still unknown. The only function known for DPA is its usefulness as a carrier for transporting pharmaceutical agents into brain [Japanese Patent Publication (Kokai) No. 61-204136 (1986)]. It is expected, however, that DPA may play a  
15 physiological role in the animal body, since it is known that DPA increases in compensation for a lack of DHA in an animal body [Homayoun et al., J. Neurochem., 51:45 (1988); Hamm et al., Biochem. J., 245:907 (1987); and Rebhung et al., Biosci. Biotech. Biochem., 58:314 (1994)].  
20

If one intends to obtain DHA and/or DPA from fish oil, several disadvantages exist, for example, the low content of the desired fatty acids, the inability to  
25 maintain a stable source of fish oil due to the migration of fish, or the offensive odor inherent in fish oil. In addition, it is difficult to obtain lipids with reliable quality, since fish oil additionally contains unsaturated fatty acids such as arachidonic acid (ARA) and  
30 eicosapentaenoic acid (EPA), which makes the lipids susceptible to oxidization.

Besides fish oil, lipids accumulated in cultured

- 3 -

cells of a microorganism having an ability to produce DHA and/or DPA is considered as a source of DHA and/or DPA. For example, the following microorganisms are known to produce DHA and/or DPA: Vibrio marinus ATCC 15381, a bacterium isolated from the deep sea; Vibrio bacteria isolated from an intestines of a deep-sea fish; flagellate fungi such as Thraustochytrium aureum ATCC 34304, Thraustochytrium sp. ATCC 28211, ATCC 20890 and ATCC 20891, Schizochytrium sp. ATCC 20888 and ATCC 20889 (U.S. Patent No. 5,340,742), Thraustochytrium SR21 strain (Nippon Nogei Kagaku Kaishi, vol.69, extra edition. July 5, 1995), and Japonochytrium sp. ATCC 28207 [Japanese Patent Publication (Kokai) No. 1-199588 (1989)]; micro-algae such as Cyclotella cryptica, Crypthecodinium cohnii [Japanese Patent Publication (Kohyo) No. 5-503425 (1993)], and Emiliana sp. [Japanese Patent Publication (Kokai) No. 5-308978 (1993)].

In using any of the above-mentioned microorganisms, however, several problems exist, for example, a low yield of DHA and/or DPA, a requirement of a prolonged culture period for obtaining a sufficient amount of DHA and/or DPA, or a requirement of a specific medium or culture condition for production. When an alga such as Emiliana sp. is utilized for the production, a high yield of DHA may be accomplished, although there may exist a disadvantage that the culture steps are complicated due to the requirement of light for cultivation. Consequently, such a process is not suitable for industrial production.

Thus, the present invention described herein makes possible the advantage of providing a process which

- 4 -

can produce DHA and/or DPA as well as lipids containing DHA and/or DPA using an inexpensive and conventional medium and simple steps for production, in a short period and in a high yield.

5

The present invention provides a process for preparing lipids containing DHA and/or DPA comprising cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce DHA and/or DPA, and recovering the lipids from the culture.

10

The present invention also provides a process for preparing DHA and/or DPA comprising cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce DHA and/or DPA, recovering the lipids from the culture, and separating the DHA and/or DPA from the lipids.

15

#### DISCLOSURE OF THE INVENTION

20

A process for preparing lipids containing docosahexaenoic acid and docosapentaenoic acid according to the present invention comprises cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid, and recovering said lipids from a culture.

25

A process for preparing docosahexaenoic acid according to the present invention comprises cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosahexaenoic acid, recovering said lipids from the

30

- 5 -

culture, and separating said docosahexaenoic acid from said lipids.

5 A process for preparing docosapentaenoic acid according to the present invention comprises cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosapentaenoic acid, recovering said lipids from the culture, and separating said docosapentaenoic acid from  
10 said lipids.

The present invention provides cells of a micro-organism belonging to the genus Ulkenia containing lipids containing docosahexaenoic acid and/or docosapentaenoic  
15 acid.

The present invention provides an Ulkenia sp. SAM2179 strain having the ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid.  
20

The present invention provides a nutrient-supplementing food, a formula suitable for feeding infants, a formula suitable for feeding immature infants, a baby food, a food for expectant or nursing mothers, a geriatric food, an enteral agent for promoting nutrition, a  
25 feed for animals, an additive for a feed for animals, and a bait for microorganisms for baits containing the lipids obtained by any one of the above-mentioned processes.

30 A process for preparing a structural lipids containing docosahexaenoic acid and docosapentaenoic acid of the present invention comprises cultivating in a medium a microorganism belonging to the genus Ulkenia having the

ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid, recovering said lipids from a culture, and treating said lipids with fungal lipase to convert fatty acids at positions 1 and 3 into middle chain (C: 8-12, see "SEIKAGAKUJITEN"(second edition) pp.834, TOKYO KAGAKUDOJIN (1990)) fatty acids.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a liquid chromatogram of triacylglycerols in neutral lipid obtained by the present invention.

#### BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is described in more detail below. As used herein, the term "docosahexaenoic acid" or "DHA" refers to the (n-3) series of docosahexaenoic acid. As used herein, the term "docosapentaenoic acid" or "DPA" refers to the (n-3) series and/or (n-6) series of docosapentaenoic acid. The terms "fats", "lipids" and "oil" are used herein in the same meaning.

Any microorganisms belonging to the genus Ulkenia can be used in the process of the present invention, as long as they have the ability to produce DHA and/or DPA. For example, Ulkenia sp. SAM 2180 and SAM 2179 strains isolated from sea water by the present inventors can be used. Among these strains, the SAM 2179 strains produces both DHA and DPA to a greater degree. This strain was deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (address: 1-3, Higashi 1 chome Tsukuba-shi Ibaraki-ken 305, JAPAN), on July 23, 1996 and assigned an accession



- 7 -

number FERM BP-5601.

The mycological characteristics of the Ulkenia sp. SAM 2179 and SAM 2180 strains are as follows. When these microorganisms were cultured in a KMV liquid medium (Fuller. M. and A. Jaworski eds.; Zoosporic Fungi in Teaching & Research VII + 303pp., 1987. Southeastern Publishing Corporation, Athens) at 20°C in the dark, globose or oval cells were observed, and biflagellate zoospores were also observed. However, a network of ectoplasm filaments was not observed. Accordingly, these microorganisms were classified into fungi belonging to Thraustochytriales with reference to "Icons of the Japanese Water Mould with Precise Explanation" by Yosio Kobayasi and Kazuko Konno (published privately by the authors at their own expense, p.169, 1986). Furthermore, these microorganisms formed rhizoids, lacked apophyses, and formed amoeba-like cells in the KMV liquid medium. Therefore, they were identified as fungi belonging to the genus Ulkenia, and the two isolates were designated as Ulkenia sp. SAM 2179 and SAM 2180, respectively.

The microorganism belonging to the genus Ulkenia used in the process of the present invention is not limited to a wild-type strain, but may also include a mutant or a recombinant strain. Thus, the use of a mutant or a recombinant strain designed to efficiently produce DHA and/or DPA falls within the scope of the present invention. Such mutants or recombinant strains include microorganisms designed to contain a higher percentage of DHA and/or DPA in lipids, a higher total amount of the lipids, or both, in comparison with the percentage or the amount produced by the original wild-type strain, utiliz-

- 8 -

ing the same substrates. The wild-type strain according to the present invention contains at least 25 % DHA and/or 5% DPA, preferably 40-48 % DHA and/or 8-13 % DPA in the lipids. Furthermore, the wild-type strain according to the present invention contains at least 3 g of DHA and/or 0.5 g of DPA, preferably 5 g of DHA and/or 1 g of DPA per liter of medium. In addition, microorganisms designed to produce a comparable amount of DHA and/or DPA with the corresponding wild-type strain, efficiently utilizing substrates with a superior cost performance, are also contemplated.

The microorganisms according to the present invention are cultured by inoculating a liquid or solid medium with a pre-culture of the microorganisms. The medium may or may not contain natural or artificial sea water.

Any conventionally used carbon sources including, for example, but not limited to, carbohydrates such as glucose, fructose, xylose, saccharose, maltose, soluble starch, fucose, glucosamine and dextran, as well as oleic acid, fats such as soybean oil, glutamic acid, molasses, glycerol, mannitol, and sodium acetate may be used as a carbon source to be added to the medium.

Natural nitrogen sources such as peptone, yeast extract, malt extract, meat extract, casamino acid and corn steep liquor, soybean cake, organic nitrogen sources such as sodium glutamate and urea, and inorganic nitrogen sources such as ammonium acetate, ammonium sulfate, ammonium chloride and ammonium nitrate may be used as a nitrogen source.

- 9 -

Furthermore, phosphates such as potassium phosphate and potassium dihydrogen phosphate, inorganic salts such as ammonium sulfate, sodium sulfate, magnesium sulfate, iron sulfate, copper sulfate, magnesium chloride and calcium chloride and vitamins may be added as  
5 micronutrients, if required.

The amount of these components in the medium is not specifically defined, as long as the concentrations  
10 of the components do not have a harmful effect on the growth of microorganisms. In general, the carbon sources may be added at a concentration of 20 to 180 g per liter of medium, and the nitrogen sources may be added at a concentration of 0.6 to 6 g per liter of medium. Preferably,  
15 the amount of the nitrogen source is increased in correspondence with the increase in the amount of the carbon source.

After preparing the medium, its pH is adjusted to  
20 the range between 3.0 and 8.0, preferably between 3.5 and 5.0, more preferably between 3.5 and 4.5, using a suitable acid or base, and then the medium is sterilized by autoclaving or the like. Cultivation of a microorganism is usually carried out for 2 to 7 days, preferably for 2  
25 to 5 days, at 10 to 35°C, preferably at 17 to 30°C, either with aeration-agitation, with shaking, or in a stationary culture.

Furthermore, precursors of DHA and/or DPA may be  
30 added to the medium in order to accelerate the production of DHA and/or DPA. For example, hydrocarbons such as tetradecane, hexadecane and octadecane, fatty acids such as oleic acid, linoleic acid and  $\alpha$ -linolenic acid, or

- 10 -

salts (e.g. sodium or potassium salts) or esters thereof are used as precursors. Furthermore, fats containing these fatty acids as a constituent (e.g. olive oil, soybean oil, cottonseed oil or palm oil) may be added.  
5 These components may be used alone or in combination with one another.

Carbon sources, nitrogen sources, precursors or the like may be added to the medium before or during the  
10 cultivation. The addition of these components may be carried out once, repeatedly or continuously.

In order to recover lipids containing DHA and/or DPA in a suitable yield for practical use, it is preferable to use a liquid medium and to cultivate with  
15 aeration-agitation. A conventional agitation-fermentor or a bubble column fermentor may be used.

By cultivating as described above, lipids containing DHA and/or DPA is produced and accumulated in  
20 cells. When a liquid medium is used, lipids which contains DHA and/or DPA may be recovered from a culture, or a sterilized culture, during the cultivation period, from a culture, or a sterilized culture, at the end of cultivation, or from cultured cells, or dried cells, collect-  
25 ed from any one of the above-mentioned cultures. As used herein, the term "culture" includes cultured cells, dried cultured cells and processed cultured cells as well as culture broth containing cells and culture supernatant.

30 DHA and/or DPA may be isolated from lipids containing DHA and/or DPA recovered from cultured cells, as follows. After cultivation, cells are collected from the

- 11 -

culture by conventional solid/liquid separation means such as centrifugation and filtration. The cells are extensively washed with water, and preferably, they are then dried. The drying of the cells may be carried out by freeze-drying, air-drying or the like. The dried cells are then destroyed, for example, by means of dyno-mill or ultrasonication, and lipids are extracted from the cells with an organic solvent, preferably under nitrogen stream. Organic solvent such as ether, hexane, methanol, ethanol, chloroform, dichloromethane or petroleum ether may be used. Alternate extraction with methanol and petroleum ether or extraction with a mixed solvent system of chloroform/methanol/water may also be used. A high concentration of lipids containing DHA and/or DPA is obtained by evaporating the organic solvent from the extract under a reduced pressure.

Alternatively, the extraction may be carried out with wet cells. In this case, a solvent compatible with water such as methanol and ethanol, or a mixed solvent compatible with water consisting of the alcohol(s) and water and/or other solvents may be used. The other procedures are as described above.

The amount of DHA in the lipids obtained as described above is at least 3 g per liter of culture, preferably 5 g per liter of culture. The amount of DPA in the lipids is at least 0.7 g per liter of culture, preferably 1.0 g per liter of culture.

In the lipids obtained as described above, DHA and/or DPA are present in the form of a neutral lipids (e.g. triacylglycerol) or a polar lipids (e.g.

- 12 -

phosphatidylcholine phosphatidylethanolamine or  
phosphatidylinositol). Purification of triacylglycerols  
containing DHA and/or DPA from lipids containing DHA  
and/or DPA recovered from a culture is carried out by  
5 using a conventional method such as cooling-separation or  
column chromatography.

Typically, the content of neutral lipids in the  
lipids of the present invention is very high (more than  
10 90 % of total lipids). The representative composition of  
fatty acids in the neutral lipids is as follows. Palmitic  
acid: 30-38 %; (n-3) DHA: 40-48 %; (n-6) DPA: 8-13 %; (n-  
3) EPA: 0-1 %; ARA: 0-0.6 %; other fatty acids: 10-20 %.

15 The neutral lipids from the lipids of the present  
invention contain at least 85 % triacylglycerols, prefer-  
ably at least 90 % triacylglycerols. The amount of  
diacylglycerols or monoacylglycerols in the neutral  
lipids is very low. Free sterol and/or sterol ester also  
20 is contained in an amount of 1-3 %. Typically, the  
following molecular species are found in the triacylgly-  
cerols: 16:0-16:0-22:5, 16:0-16:0-22:6, 16:0-22:5-22:6,  
16:0-22:6-22:6, 22:5-22:6-22:6, and 22:6-22:6-22:6,  
wherein, for example, "16:0" means a fatty acid having  
25 "16" carbon atoms and no ("0") double bonds. It is inter-  
esting that triacylglycerols consisting of only polyun-  
saturated fatty acids exist in the lipids of the present  
invention.

30 Separation of DHA and/or DPA from lipids contain-  
ing DHA and/or DPA may be carried out by hydrolyzing the  
lipids, and then concentrating and separating the result-  
ing mixed fatty acids or mixed fatty acid esters prepared

- 13 -

therefrom, by using a conventional method such as urea-addition, cooling-separation or column chromatography.

5           The DHA and/or DPA as well as the lipids containing DHA and/or DPA obtained as described above can be added to various foods, feedstuffs or baits to counter a deficiency of DHA and/or DPA. Examples of such foods include, for example, nutrient-supplementing foods,  
10   formula suitable for feeding infants or immature infants, health foods, functional foods (such as an enteral agent for promoting nutrition), baby foods, foods for expectant or nursing mothers and geriatric foods. Feedstuffs include feed for domestic animals such as pigs and cows,  
15   feed for domestic fowl such as chickens, pet foods for dogs, cats and the like, and feed for fish breeding. Baits include, for example, those for microorganisms (so-called zooplanktons) which are given as a bait for culturing fish and shellfish.

20           Particularly, for feedstuffs and baits, it is advantageous and economical to use a culture of a microorganism of the present invention, cells collected from the culture, or a residue of the cells after the recovery  
25   of the lipids. For example, cells of microorganisms which produce DHA and/or DPA may be directly used to feed fry (the young of fishes), instead of indirectly feeding them through zooplanktons and the like. These materials may be used after drying or sterilizing, if necessary.

30           The lipids of the present invention may be used for producing poultry eggs enriched with DHA and/or DPA, which are obtained by feeding poultries for ovum collec-

- 14 -

tion (preferably chickens) with feed containing the lipids of the present invention. Egg yolk oil enriched with DHA and/or DPA may also be produced by extracting oil from such poultry eggs or egg yolk therefrom using a conventional method. Formula suitable for feeding infants and immature infants, baby food, food for expectant and nursing mothers containing such egg yolk oil are also contemplated.

Efforts have been made for long to make the composition of powdered milk for babies similar to that of human milk. In particular, it is important to make the composition of the main ingredients of human milk (i.e., protein, fat, and sugar) in powdered milk similar to that of human milk. Regarding lipids, it has been a problem that the conventional powdered milk is deficient in polyunsaturated fatty acids, which are inherently contained in human milk. Several reports on the composition of unsaturated fatty acids in human milk have been published (for polyunsaturated fatty acids in American, European, and African mothers' milk, see INFORM, 6(8):940-946 (1995); for polyunsaturated fatty acids in Japanese mothers' milk, see JJPEN, 13(9):765-772 (1991)).

Recently, it was demonstrated that ARA and DHA, both of which are contained in human milk, are effective in the growth of babies ("Advances in Polyunsaturated Fatty Acid Research", Elsevier Science Publishers, pp.261-264 (1993)). The importance of ARA and DHA in the increase of height and the development of brain was also reported (Proc. Natl. Acad. Sci. USA, 90:1073-1077 (1993); Lancet, 344:1319-1322 (1994)).



- 15 -

Therefore, there exists an increasing interest in adding ARA and DHA to modified milk. Modified milk containing fish oil as a source for DHA are now on the market. Fish oil also contains EPA, which is scarcely present in human milk, and which has been reported to render an adverse effect on growth of immature infants ("Advances in Polyunsaturated Fatty Acid Research", Elsevier Science Publishers, pp.261-264 (1993)). The lipids of the present invention are suitable as an additive to modified milk, since the content of EPA is extremely low. The lipids of the present invention can be added to baby food as well.

The lipids of the present invention may be added to food, such as nutrient-supplementing food, geriatric food, or health food, for the supply of DHA and/or DPA or for the maintenance of health. The food composition may be in the form of solid or liquid foods, or foods containing oils. The content of lipids in the food is preferably between 0.001 to 50 % by weight, depending on the nature of the food to which the lipids are added.

Examples of foods containing oils include natural foods inherently containing oils (such as meat, fish or nut), food to which the lipids are added upon cooking (such as soup), food for which the lipids are used as heating medium (such as doughnuts), fat food (such as butter), processed food into which the lipids are added upon processing (such as cookies), or food to which the lipids are sprayed or applied upon completion of processing (such as hard biscuits). The lipids (or separated DHA and/or DPA) of the present invention may also be added to agricultural food, fermentation food, livestock food, sea

- 16 -

food, or drink, which does not contain fats.

Alternatively, the lipids of the present invention may also be added to a functional food which exhibits the physiological activity of DHA and/or DPA for the recovery of a lowered function of body or for the prevention of lowering it. The functional food of the present invention may be in a form of a medical formulation or in a processed form (such as an enteral agent for promoting nutrition, powder, granule, troche, internal solution, suspension, emulsion, syrup and the like) in which the lipids of the present invention are combined with protein, saccharide, lipid, trace elements, vitamin, emulsifying agent, or perfume.

Furthermore, the lipids of the present invention may be used as an additive for a cosmetic or a wash, or a starting material for producing a derivative thereof to be used as a medicament.

Hereinafter, the present invention will be specifically described by way of examples. However, the invention is not limited to the examples.

(Example 1)

Production of lipids using microorganisms belonging to the genus *Ulkenia* (1)

The *Ulkenia* sp. SAM 2180 and SAM 2179 strains were cultivated in a 5 liter (L) volume fermentor (jar fermentor) containing 3 L of medium having the following composition under the following culture conditions.

- 17 -

## (1) Medium composition

- |   |                                   |     |
|---|-----------------------------------|-----|
|   | 1) Glucose (g/L):                 | 60  |
|   | 2) Potassium phosphate (g/L):     | 3   |
|   | 3) Ammonium sulfate (g/L):        | 2   |
| 5 | 4) Corn steep liquor (g/L):       | 0.7 |
|   | 5) 50 % Artificial sea water (L): | 1   |
|   | 6) pH:                            | 4.0 |

## (2) Culture conditions

- |    |  |     |
|----|--|-----|
| 10 | 1) Culturing temperature (°C):                       | 28  |
|    | 2) Aeration amount (VVM):                            | 0.5 |
|    | 3) Agitation rate (rpm):                             | 300 |
|    | 4) pH Adjustment: maintained at pH 4 with 10 % (w/v) |     |
|    | sodium hydroxide and 1 M sulfuric acid               |     |

15

After cultivation, cells were collected by centrifugation and freeze-dried, then the amount (by weight) of cells per liter of medium was measured. Destruction of the cells and extraction of the lipids were then carried out by adding a mixture of chloroform/methanol (2:1, v/v) to the dried cells at a ratio of 100 volumes per weight of the cells and homogenizing the mixture in the presence of glass beads. After washing the extract according to the Folch method, the solvent was evaporated to obtain purified lipids, and the weight of the lipids was then measured.

20

25

In order to estimate the fatty acid composition of the resulting purified lipids, fatty acid methyl esters were prepared by dissolving a portion of the lipids in a mixed solution of an equal amount of methanol solution containing 10 % HCl and dichloromethane, and heat-treating the mixture at 60°C for 2 hours. The esters

30

- 18 -

were then subjected to gas chromatography to analyze the fatty acid composition. The separation conditions for the gas liquid chromatography were as follows.

5 (3) Separation conditions

- 1) Column : capillary column TC-70 (GL Science Co., LTD.), inner diameter 0.25 mm x length 30 m
- 2) Flow rate : 0.8 ml/min, 100 kPa (column head pressure)
- 10 3) Carrier gas : nitrogen gas
- 4) Column temperature : rising mode, 170-220°C (4°C/min.)
- 5) Detection : FID

15 The results are shown in the following Tables 1 and 2.

Table 1

20	Strain	Cultivation time (days)	Dry cell weight (g)*1	Total amount of lipids (g)*1	Percent of lipids content (wt %)*2	Amount of DHA (g)*1	Amount of DPA (g)*1
25	SAM2180	3	23.2	14.1	61	4.0	0.9
	SAM2179	3	19.5	11.9	61	5.5	1.3

\*1) Weight per liter of medium

\*2) Percentage versus dried cells

30

- 19 -

Table 2

Strain	14:0	15:0	16:0	17:0	18:0	20:4 (AA)	20:5 (EPA)	22:5 (DPA)	22:6 (DHA)
SAM2180	2.7	2.4	55.0	1.0	1.4	-	0.2	6.7	28.7
SAM2179	2.4	0.9	37.2	0.3	0.8	0.4	0.6	10.6	46.2

(Example 2)

Production of lipids using microorganism belonging to the genus *Ulkenia* (2)

The *Ulkenia* sp. SAM 2179 strain was cultivated in a 5 L volume fermentor (jar fermentor) containing 3 L of medium having the following composition under the following culture conditions.

## (1) Medium composition

- 1) Glucose (g/L): 60
- 2) Potassium phosphate (g/L): 3
- 3) Ammonium sulfate (g/L): 2
- 4) Magnesium chloride (g/L): 1.3
- 5) Sodium sulfate (g/L): 1
- 6) Calcium chloride (g/L): 0.3
- 7) Corn steep liquor (g/L): 0.7
- 8) pH: 4.0

## (2) Culture conditions

- 1) Culturing temperature (°C): 28
- 2) Aeration amount (VVM): 0.5

- 20 -

3) Agitation rate (rpm): 300

4) pH Adjustment: maintained at pH 4 with 10 % (w/v)  
sodium hydroxide and 1 M sulfuric acid

5           After cultivation, cells were collected by  
centrifugation and freeze-dried, then the amount (by  
weight) of cells per liter of medium was measured.  
Destruction of the cells and extraction of the lipids  
were then carried out by adding a mixture of chloro-  
10   form/methanol (2:1, v/v) to the dried cells at a ratio of  
100 volumes per weight of the cells and homogenizing the  
mixture in the presence of glass beads. After washing the  
extract according to the Folch method, the solvent was  
evaporated to obtain purified lipids, and the weight of  
15   the lipids was then measured.

In order to estimate the fatty acid composition  
of the resulting purified lipids, fatty acid methyl  
esters were prepared by dissolving a portion of the  
20   lipids in a mixed solution of an equal amount of methanol  
solution containing 10 % HCl and dichloromethane, and  
heat-treating the mixture at 60°C for 2 hours. The esters  
were then subjected to gas chromatography to analyze the  
fatty acid composition. The separation conditions for the  
25   gas liquid chromatography were as described in Example 1.

The results are shown in the following Tables 3  
and 4.

30

- 21 -

Table 3

Strain	Cultivation time (days)	Dry cell weight (g)*1	Total amount of lipids (g)*1	Percent of lipids content (wt %)*2	Amount of DHA (g)*1	Amount of DPA (g)*1
SAM2179	3	21.5	12.0	56	5.5	1.5

- \*1) Weight per liter of medium  
 \*2) Percentage versus dried cells

Table 4

Strain	14:0	15:0	16:0	17:0	18:0	20:4 (AA)	20:5 (EPA)	22:5 (DPA)	22:6 (DHA)
SAM2179	2.0	1.5	34.3	0.5	0.9	0.7	0.7	12.4	45.8

(Example 3)

Analysis of lipids from Ulkenia sp. SAM 2179

Neutral lipids and polar lipids were separated from the lipids obtained in Example 1 by conventional liquid-liquid partition technique using hexan and 90 % methanol. 0.92 g of neutral lipids and 0.05 g of polar lipids were obtained from 1 g of the lipids, respectively. The resulting neutral lipids and polar lipids were analyzed using thin-layer chromatography. Color development was accomplished by using sulfuric acid, then the

- 22 -

identity of the resulting spots were confirmed by comparing their Rf values with those of standard lipids.

5           More than 90 % of the neutral lipids were triacylglycerols. The polar lipids consist of phosphatidylcholine (60-80 %), phosphatidylethanolamine (5-20 %) and phosphatidylinositol (2-8 %).

10           The triacylglycerols in the neutral lipids were further analyzed by separating molecular species on liquid chromatography (column: ODS column; mobile phase: acetone/acetonitrile (3:2); detection: differential refractometer) (see Figure 1). The resulting peaks were isolated and, after hydrolysis, converted to  
15 methylesters. The fatty acid residues were determined by using gas liquid chromatography.

20           The five main peaks were identified as shown in Table 5. Triacylglycerols were composed of 12.8 % 1,2,3-tri-docosaheptaenoyl-triacylglycerol and 8.0 % 1-docosapentaenoyl-2,3-di-docosaheptaenoyl-triacylglycerol. About 20 % of the total triacylglycerols were composed of tri-polyunsaturated fatty acids.



- 23 -

Table 5

Peak	Molecular species	Ratio (%)
1	22:6-22:6-22:6	12.8
2	22:5-22:6-22:6	8.0
3	16:0-22:6-22:6	18.3
4	16:0-22:5-22:6	8.1
5	16:0-16:0-22:6	10.8

(Example 4)

#### Determination of fatty acid residues binding site in triacylglycerols

The binding site of the fatty acid residue in the triacylglycerols obtained in Example 3 was analyzed as follows. The triacylglycerols obtained in Example 3 (molecular species: 16:0-16:0-22:6) were dried, and treated with lipase (from Rhizopus japonicus) specific for position 1,3. The fatty acid residue was identified using GC/MS after the resulting 2-monoacylglycerols were trimethylsilylated. Lipase treatment was performed in 2 ml of 50 mM acetate buffer (pH 5.5) with 1000 units of lipase at 35°C for 30 minutes. The reaction products were extracted with ether and trimethylsilylated using commercially available trimethylsilylating agent.

A fragment peak corresponding to the molecular weight of monoacylglycerols to which 22:6 is attached was observed, indicating that the triacylglycerols are 16:0-22:6-16:0 to which fatty acid residues of 22:6 are at-

- 24 -

tached on position 2 of glycerol backbones.

(Example 5)

Preparation of modified milk containing DHA and DPA

5

Modified milk containing DHA and DPA was prepared by adding 0.44 g of the lipids in Example 1, which contains 46.2 % DHA and 10.6 % DPA, to 100 g of powdered milk.

10

The composition of DHA and DPA in the resulting milk were 0.80 % and 0.19 % of total fatty acids, respectively, which was similar to that of human milk.

15

(Example 6)

Preparation of structural lipids containing DHA and DPA

20

25

30

50 ml of lipase solution (5,600 U/ml, lipase specific for position 1,3 from Rhizopus delemar) was mixed with 2.5 g of CaCO<sub>3</sub> as an immobilizing carrier. The enzyme was immobilized and precipitated by adding 40 ml of acetone to the mixture, and the immobilized enzyme was then dried. The specific activity of the resulting immobilized enzyme was 9.3 U/mg. 120 mg of the immobilized enzyme was mixed with 1 g of DHA and DPA-containing lipids obtained from SAM2180 in Example 1, 2 g of caprylic acid, and 60 mg of water with agitation at 30°C for 8 hours. Triacylglycerols were then recovered from the reaction mixture using a conventional method and the fatty acid composition of the triacylglycerols was determined. The results are shown in Table 6.

- 25 -

Table 6

	8:0	14:0	15:0	16:0	17:0	18:0	20:4	20:5	22:5	22:6
							(AA)	(EPA)	(DPA)	(DHA)
No treatment	0.0	2.7	2.4	55.0	1.0	1.4	0.0	0.2	6.7	28.7
After lipase treatment	36.2	1.8	1.2	17.6	1.0	1.8	0.0	0.2	7.3	30.4

10

More than 30 % triacylglycerols have polyunsaturated fatty acids in the SN2 position of glycerols. So, these lipids are suitable for making structural lipids which contain middle chain fatty acids in the SN1 and SN3 position of glycerols and polyunsaturated fatty acids in the SN2 position of glycerols.

15

#### INDUSTRIAL APPLICABILITY

20

Lipids which contain a high amount of DHA and/or DPA and a low amount of EPA can be obtained by the process of the present invention. DHA and/or DPA may also be obtained by further separating it from the lipids.

25

The lipids containing DHA and/or DPA, the separated DHA and the separated DPA of the present invention are useful as an additive for foods, feedstuffs, baits, medicament and the like. For feedstuffs or baits, cells containing DHA and/or DPA of the present invention may be used. Poultry egg or poultry egg yolk enriched for DHA and/or DPA may be produced by feeding poultry with the feedstuffs of the present invention.

30

- 26 -

CLAIMS

1. A process for preparing lipids containing docosahexaenoic acid and docosapentaenoic acid comprising:  
5       cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid, and  
10       recovering said lipids from a culture.
2. A process for preparing docosahexaenoic acid comprising:  
15       cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosahexaenoic acid,  
      recovering said lipids from the culture, and  
      separating said docosahexaenoic acid from said lipids.  
20
3. A process for preparing docosapentaenoic acid comprising:  
      cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids  
25       containing docosapentaenoic acid,  
      recovering said lipids from the culture, and  
      separating said docosapentaenoic acid from said lipids.
- 30   4. Cells of a microorganism belonging to the genus Ulkenia containing lipids containing docosahexaenoic acid and/or docosapentaenoic acid.

- 27 -

5. An Ulkenia sp. SAM2179 strain having the ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid.
- 5      6. A nutrient-supplementing food containing the lipids obtained by the process according to any one of claims 1 to 3.
- 10      7. A formula suitable for feeding infants containing the lipids obtained by the process according to any one of claims 1 to 3.
- 15      8. A formula suitable for feeding immature infants containing the lipids obtained by the process according to any one of claims 1 to 3.
- 20      9. A baby food containing the lipids obtained by the process according to any one of claims 1 to 3.
- 25      10. A geriatric food containing the lipids obtained by the process according to any one of claims 1 to 3.
- 30      11. An enteral agent for promoting nutrition containing the lipids obtained by the process according to any one of claims 1 to 3.
12. A feed for animals containing the lipids obtained by the process according to any one of claims 1 to 3.
13. An additive for a feed for animals containing the lipids obtained by the process according to any one of claims 1 to 3.

- 28 -

14. A bait for microorganisms for baits containing the lipids obtained by the process according to any one of claims 1 to 3.

5 15. A food for expectant or nursing mothers containing the lipids obtained by the process according to any one of claims 1 to 3.

10 16. A process for preparing structural lipids containing docosahexaenoic acid and docosapentaenoic acid comprising:

15 cultivating in a medium a microorganism belonging to the genus Ulkenia having the ability to produce lipids containing docosahexaenoic acid and docosapentaenoic acid,

recovering said lipids from a culture, and

treating said lipids with fungal lipase to convert fatty acids at positions 1 and 3 into middle chain fatty acids.

1/1




Fig. 1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 97/01946

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12P 7/64, A61K 31/20, A23L 1/30

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, BIOSIS, WPI, USPATFULL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5397591 A (DAVID J. KYLE ET AL), 14 March 1995 (14.03.95), see column 7, lines 1-32 --	6-15
X	WPI accession no. 97-161410, NISSHIN OIL MILLS LTD: "Medical compositions containing fats and oils - comprises mixed tri:glyceride(s) contg. fatty acids, useful in decreasing blood cholesterol and preven- tion of hyperlipaemia or arteriosclerosis"; & JP,A,9030962, 970204 --	6-15
X	US 5340742 A (WILLIAM R. BARCLAY), 23 August 1994 (23.08.94) -----	6-15

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

30 Sept 1997

14.10.97

Name and mailing address of the ISA/

Authorized officer



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Carolina Gómez Lagerlöf



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/JP 97/01946

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5397591 A	14/03/95	US 5492938 A	20/02/96
		AU 660162 B	15/06/95
		AU 7330291 A	03/09/91
		CA 2076018 A	14/08/91
		EP 0515460 A	02/12/92
		IL 97126 A	15/03/95
		JP 5503425 T	10/06/93
		US 5407957 A	18/04/95
		WO 9111918 A	22/08/91
<hr/>			
US 5340742 A	23/08/94	AU 5327194 A	09/05/94
		EP 0669809 A	06/09/95
		JP 8502405 T	19/03/96
		US 5518918 A	21/05/96
		WO 9408467 A	28/04/94
		US 5130242 A	14/07/92
		US 5340594 A	23/08/94
		US 5656319 A	12/08/97
		AU 657259 B	09/03/95
		AU 6719590 A	13/06/91
		CA 2072978 A	18/05/91
		EP 0512997 A,B	19/11/92
		JP 8509355 T	08/10/96
		WO 9107498 A	30/05/91